In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

Hepatology

Volumn 31, Issue 1, 2000, Pages 219-224

  Xiong, Xiaofeng ^a   Yang, Huiling ^a   Westland, Christopher E ^a   Zou, Ruiming ^a   Gibbs, Craig S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; FAMCICLOVIR; LAMIVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYMATIC ASSAY; ENZYME INHIBITION; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0033977128     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310132     Document Type: Article

References (15)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
3. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
4. Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BCY, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. HEPATOLOGY 1997:25:241-244.
5. Lai CL, Yuen MF, Cheng CC, Wong WM, Cheng TK, Lai YP. An open comparative study of lamivudine and famciclovir in the treatment of chronic hepatitis B infection [Abstract]. HEPATOLOGY 1998;28(suppl): 318A.
6. Lai CL, Chien RN, Leung NWY, Chan TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
7. Tanikawa K, Hayashi N, Ichida F, Lino S, Kumada H, Ogawa N, Okida K, et al. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [Abstract]. HEPATOLOGY 1997;26(suppl):259A.
8. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology 1997:113:1258-1263.
9. Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai Dl, Ng KY, et al. Lamivudine (100mg od) for 1 year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection [Abstract]. HEPATOLOGY 1997;26(suppl):357A.
10. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996;3:211-215.
11. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study [Abstract]. HEPATOLOGY 1996;24(suppl):188A.
12. Gilson RJ, Chopra K, Murray-Lyon IM, Newell AM, Nelson MR, Tedder RS, Toole JJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. HEPATOLOGY 1996;24(suppl):281A.
13. Gilson RJC, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Murray A, Jaffe HS, et al. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection [Abstract]. HEPATOLOGY 1998; 28(suppl):491A.
14. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies [Abstract]. HEPATOLOGY 1998;28(suppl):317A.
15. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. HEPATOLOGY 1996:24:996-1002.